The effects of obesity on drug pharmacokinetics in humans.
about
Impact of obesity on drug metabolism and elimination in adults and children.Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.The effects of gastric bypass surgery on drug absorption and pharmacokinetics.Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature.Interethnic differences in pharmacokinetics of antibacterials.Altered drug disposition following bariatric surgery: a research challenge.Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.Risk factors for polyuria in a cross-section of community psychiatric lithium-treated patients.Information provision for antibacterial dosing in the obese patient: a sizeable absence?Effectiveness and toxicity of high-dose cyclophosphamide in obese versus non-obese patients receiving allogeneic hematopoietic stem cell transplant.Drug dosing in obese adults.Lean-scaled weight: a proposed weight scalar to calculate drug doses for obese patients.The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults.Lean Body Weight Is Not a Weight Scalar for Estimating Drug Doses in Morbid Obesity.Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: a rebuttal.To cap or not to cap: chemotherapy dosing in obese adult hematology patients.The future of genomic testing in primary care: the changing face of personalized medicine.Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
P2860
Q37997025-B4624CC8-6D0E-4D1F-A2AC-84FAF53D2956Q38019839-1784B6BA-2C68-457F-91AA-A27564DDBC9AQ38045375-31E41FFD-DA4E-4E27-921E-07C31ADA5289Q38106836-7C75814A-6F8C-4003-86F7-23298201CB93Q38266806-300C359D-91DC-4388-BC6A-EF8462298CBCQ38381805-0757A516-060C-48C4-98DF-D1FAF5F3D056Q39033125-3CBAD45C-2975-4434-9BC5-C23781F7B895Q39152568-35E7B1EC-0B4D-4ADA-A484-9E045F74C4B9Q40570741-3ABB12E2-1F1E-45A2-A087-C28F1B7EAD01Q45003576-154D82FB-C187-4DE0-9B6E-5428757FDA1FQ47154923-06BF5C82-51C8-4FDE-B077-4F21ED9BDC06Q47269913-F76C93AF-E65D-4376-B289-C531B2F53DA9Q47323100-18E0E0F7-0330-4DA6-B229-06AA03AB51D3Q47381465-F749A13A-9E53-41B1-9357-0B9678D99F6BQ47911043-A7C72739-47F5-4D46-A490-284C3E529813Q48312577-F5A95332-402A-4C49-876B-4A3224AD8DD1Q50506593-5138E3D8-416A-4149-9A49-C7D8CA6176C4Q51101109-09422AC1-B7B4-4403-B492-6BDC6648AEB8Q53818766-A5536594-055A-4E41-B144-BE57404FCC09Q58073610-EF13E017-BF38-4D57-9994-2CEE70A86FF5
P2860
The effects of obesity on drug pharmacokinetics in humans.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The effects of obesity on drug pharmacokinetics in humans.
@en
The effects of obesity on drug pharmacokinetics in humans.
@nl
type
label
The effects of obesity on drug pharmacokinetics in humans.
@en
The effects of obesity on drug pharmacokinetics in humans.
@nl
prefLabel
The effects of obesity on drug pharmacokinetics in humans.
@en
The effects of obesity on drug pharmacokinetics in humans.
@nl
P2093
P2860
P1476
The effects of obesity on drug pharmacokinetics in humans.
@en
P2093
Bruce Green
Glynn A Morrish
Manjunath P Pai
P2860
P304
P356
10.1517/17425255.2011.570331
P407
P577
2011-03-22T00:00:00Z